<p>Blue = insulin monotherapy, green = insulin plus metformin. Time zero refers to index date plus 180 days. For the adjusted survival curves, a non-time-dependent Cox model was used, where insulin dose was modelled as the mean value for the follow-up period. The proportional hazards assumption was violated for history of cancer (all-cause mortality), history of receiving antihypertensive therapy (all-cause mortality), and serum creatinine (cancer).</p
<p>Adjusted multivariate Cox proportional hazards model for diabetes progression measured as risk of...
Observational drug safety studies may be susceptible to confounding or protopathic bias. This bias m...
<p>Kaplan-Meir survival curves for the risk of all-cause death in the study participants for all par...
<p>Notes: Final model specification: estimated cumulative insulin dose, therapy (±metformin), HbA1c,...
<p>For the overall model, there was evidence that the proportional hazards assumption was violated f...
To determine if concomitant metformin reduced the risk of death, major adverse cardiac events (MACE)...
a<p>Although not shown here, the model also included age at first insulin prescription (FIP), gender...
AIMS:To determine if concomitant metformin reduced the risk of death, major adverse cardiac events (...
Suppose we want to investigate to what extent some factor influences survival, as an example we migh...
Aims To determine if concomitant metformin reduced the risk of death, major adverse cardiac events (...
<p>Panel A shows the cumulative survival for gliclazide, glimepiride and tolbutamide and time to ins...
Aims: The objective of this nationwide study was to compare the risk of all-cause mortality, fatal a...
Observational drug safety studies may be susceptible to confounding or protopathic bias. This bias m...
Kaplan-Meier survival estimates according to the receipt of no diabetes medication, other diabetes m...
OBJECTIVEdTo add to the evidence on comparative long-term effects of insulin analog glargine versus ...
<p>Adjusted multivariate Cox proportional hazards model for diabetes progression measured as risk of...
Observational drug safety studies may be susceptible to confounding or protopathic bias. This bias m...
<p>Kaplan-Meir survival curves for the risk of all-cause death in the study participants for all par...
<p>Notes: Final model specification: estimated cumulative insulin dose, therapy (±metformin), HbA1c,...
<p>For the overall model, there was evidence that the proportional hazards assumption was violated f...
To determine if concomitant metformin reduced the risk of death, major adverse cardiac events (MACE)...
a<p>Although not shown here, the model also included age at first insulin prescription (FIP), gender...
AIMS:To determine if concomitant metformin reduced the risk of death, major adverse cardiac events (...
Suppose we want to investigate to what extent some factor influences survival, as an example we migh...
Aims To determine if concomitant metformin reduced the risk of death, major adverse cardiac events (...
<p>Panel A shows the cumulative survival for gliclazide, glimepiride and tolbutamide and time to ins...
Aims: The objective of this nationwide study was to compare the risk of all-cause mortality, fatal a...
Observational drug safety studies may be susceptible to confounding or protopathic bias. This bias m...
Kaplan-Meier survival estimates according to the receipt of no diabetes medication, other diabetes m...
OBJECTIVEdTo add to the evidence on comparative long-term effects of insulin analog glargine versus ...
<p>Adjusted multivariate Cox proportional hazards model for diabetes progression measured as risk of...
Observational drug safety studies may be susceptible to confounding or protopathic bias. This bias m...
<p>Kaplan-Meir survival curves for the risk of all-cause death in the study participants for all par...